• Hapvida clarified a commercial review of corporate health-plan contracts covering about 947,000 beneficiaries, with repricing or discontinuation expected over 12 months.
• Repricing terms remain unknown, non-uniform, contract-by-contract, region-by-region, with possible plan or co-payment changes beyond premium increases.
• It said “strong double-digit” referred to past ticket increases that did not necessarily reduce revenue, not a forecast for the current review.
• The comment was used to rebut an investor assumption that the review would only lead to top-line declines.
• Hapvida said it has no undisclosed material fact related to the review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hapvida Participações e Investimentos SA published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.